A French research study published in the New England Journal of Medicine has shown a survival benefit from a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) for patients with metastatic pancreatic cancer. Although this combination does cause more side effects.
For more information see http://www.latimes.com/health/boostersh ... 2897.story
This forum contains news that Pancreatic Cancer UK and forum users have shared over the years.
1 post • Page 1 of 1